Literature DB >> 28757146

Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization.

Yang Liu1, Jinghong Ma1, Andrew Beenken1, Lakshmi Srinivasan1, Anna V Eliseenkova1, Moosa Mohammadi2.   

Abstract

The epithelial fibroblast growth factor 9 (FGF9) subfamily specifically binds and activates the mesenchymal "c" splice isoform of FGF receptors 1-3 (FGFR1-3) to regulate organogenesis and tissue homeostasis. The unique N and C termini of FGF9 subfamily ligands mediate a reversible homodimerization that occludes major receptor binding sites within the ligand core region. Here we provide compelling X-ray crystallographic, biophysical, and biochemical data showing that homodimerization controls receptor binding specificity of the FGF9 subfamily by keeping the concentration of active FGF9 monomers at a level, which is sufficient for a normal FGFR "c" isoform binding/signaling, but is insufficient for an illegitimate FGFR "b" isoform binding/signaling. We show that deletion of the N terminus or alanine substitutions in the C terminus of FGF9 skews the delicate ligand equilibrium toward active FGF9 monomers causing off-target binding and activation of FGFR b isoforms. Our study is the first to implicate ligand homodimerization in the regulation of ligand-receptor specificity.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BaF3 cells; FGF receptor 1; X-ray crystallography; autoinhibition; fibroblast growth factor 9; homodimerization; multi-angle light scattering; specificity; surface plasmon resonance

Mesh:

Substances:

Year:  2017        PMID: 28757146      PMCID: PMC5587394          DOI: 10.1016/j.str.2017.06.016

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  46 in total

1.  Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1.

Authors:  Andrew Beenken; Anna V Eliseenkova; Omar A Ibrahimi; Shaun K Olsen; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

2.  Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.

Authors:  O A Ibrahimi; A V Eliseenkova; A N Plotnikov; K Yu; D M Ornitz; M Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

3.  FGF9 suppresses meiosis and promotes male germ cell fate in mice.

Authors:  Josephine Bowles; Chun-Wei Feng; Cassy Spiller; Tara-Lynne Davidson; Andrew Jackson; Peter Koopman
Journal:  Dev Cell       Date:  2010-09-14       Impact factor: 12.270

4.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.

Authors:  Neali D Hendrix; Rong Wu; Rork Kuick; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.

Authors:  Brian K Yeh; Makoto Igarashi; Anna V Eliseenkova; Alexander N Plotnikov; Ifat Sher; Dina Ron; Stuart A Aaronson; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

6.  Tissue interactions pattern the mesenchyme of the embryonic mouse lung.

Authors:  Molly Weaver; Lorene Batts; Brigid L M Hogan
Journal:  Dev Biol       Date:  2003-06-01       Impact factor: 3.582

7.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Authors:  Zhi Gang Li; Paul Mathew; Jun Yang; Michael W Starbuck; Amado J Zurita; Jie Liu; Charles Sikes; Asha S Multani; Eleni Efstathiou; Adriana Lopez; Jing Wang; Tina V Fanning; Victor G Prieto; Vikas Kundra; Elba S Vazquez; Patricia Troncoso; Austin K Raymond; Christopher J Logothetis; Sue-Hwa Lin; Sankar Maity; Nora M Navone
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

8.  Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene.

Authors:  Xiao-Lin Wu; Ming-Min Gu; Lei Huang; Xue-Song Liu; Hong-Xin Zhang; Xiao-Yi Ding; Jian-Qiang Xu; Bin Cui; Long Wang; Shun-Yuan Lu; Xiao-Yi Chen; Hai-Guo Zhang; Wei Huang; Wen-Tao Yuan; Jiang-Ming Yang; Qun Gu; Jian Fei; Zhu Chen; Zhi-Min Yuan; Zhu-Gang Wang
Journal:  Am J Hum Genet       Date:  2009-07       Impact factor: 11.025

9.  Fgf9 signaling regulates small intestinal elongation and mesenchymal development.

Authors:  Michael J Geske; Xiuqin Zhang; Khushbu K Patel; David M Ornitz; Thaddeus S Stappenbeck
Journal:  Development       Date:  2008-07-24       Impact factor: 6.868

10.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Authors:  P M Pollock; M G Gartside; L C Dejeza; M A Powell; M A Mallon; H Davies; M Mohammadi; P A Futreal; M R Stratton; J M Trent; P J Goodfellow
Journal:  Oncogene       Date:  2007-05-21       Impact factor: 9.867

View more
  9 in total

Review 1.  Fibroblast growth factor signalling in osteoarthritis and cartilage repair.

Authors:  Yangli Xie; Allen Zinkle; Lin Chen; Moosa Mohammadi
Journal:  Nat Rev Rheumatol       Date:  2020-08-17       Impact factor: 20.543

2.  Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration.

Authors:  Kihoon Nam; Spencer M Dean; Callie T Brown; Randall J Smith; Pedro Lei; Stelios T Andreadis; Olga J Baker
Journal:  Acta Biomater       Date:  2019-04-25       Impact factor: 8.947

3.  FGF Pyramus Has a Transmembrane Domain and Cell-Autonomous Function in Polarity.

Authors:  Vincent Stepanik; Jingjing Sun; Angelike Stathopoulos
Journal:  Curr Biol       Date:  2020-07-02       Impact factor: 10.834

4.  Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability.

Authors:  Jianlou Niu; Jing Zhao; Jiamin Wu; Guanting Qiao; Junlian Gu; Chuanren Zhou; Qi Li; Lei Ying; Dezhong Wang; Huan Lin; Xiaokun Li; Moosa Mohammadi; Zhifeng Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-03       Impact factor: 11.205

5.  Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.

Authors:  Nicholas G James; Shiazah Malik; Bethany J Sanstrum; Catherine Rhéaume; Ron S Broide; David M Jameson; Amy Brideau-Andersen; Birgitte S Jacky
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

6.  α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling.

Authors:  Gaozhi Chen; Yang Liu; Regina Goetz; Lili Fu; Seetharaman Jayaraman; Ming-Chang Hu; Orson W Moe; Guang Liang; Xiaokun Li; Moosa Mohammadi
Journal:  Nature       Date:  2018-01-17       Impact factor: 49.962

7.  FGF6 and FGF9 regulate UCP1 expression independent of brown adipogenesis.

Authors:  Farnaz Shamsi; Ruidan Xue; Tian Lian Huang; Morten Lundh; Yang Liu; Luiz O Leiria; Matthew D Lynes; Elena Kempf; Chih-Hao Wang; Satoru Sugimoto; Pasquale Nigro; Kathrin Landgraf; Tim Schulz; Yiming Li; Brice Emanuelli; Srinivas Kothakota; Lewis T Williams; Niels Jessen; Steen Bønløkke Pedersen; Yvonne Böttcher; Matthias Blüher; Antje Körner; Laurie J Goodyear; Moosa Mohammadi; C Ronald Kahn; Yu-Hua Tseng
Journal:  Nat Commun       Date:  2020-03-17       Impact factor: 14.919

8.  Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.

Authors:  Jakob Paur; Maximilian Valler; Rebecca Sienel; Karin Taxauer; Klaus Holzmann; Brigitte Marian; Andreas Unterberger; Thomas Mohr; Walter Berger; Andja Gvozdenovich; Johannes Schimming; Michael Grusch; Bettina Grasl-Kraupp
Journal:  Liver Int       Date:  2020-06-17       Impact factor: 5.828

9.  A novel heterozygous variant in FGF9 associated with previously unreported features of multiple synostosis syndrome 3.

Authors:  Ann-Charlotte Thuresson; Brittany Croft; Yasmin D Hailer; Gunnar Liminga; Carl-Göran Arvidsson; Vincent R Harley; Eva-Lena Stattin
Journal:  Clin Genet       Date:  2021-02       Impact factor: 4.438

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.